On August 15, 2023, the Board of Directors (the "Board") of MediWound Ltd. (the "Company") appointed Mr. Shmuel (Milky) Rubinstein as a new member of the Board. Mr. Rubinstein brings a distinguished record of pharmaceutical and biotechnology leadership to the Company. He is the Chairperson of the Board at Trima Pharma and serves as a board member at Strata Skin Sciences (Nasdaq: SSKN), Medison Biotech, Keystone Dental and additional private companies.

Additionally, Mr. Rubinstein has previously served as a director at Kamada (Nasdaq: KMDA), Clal Biotechnology Industries (TASE: CBI), and Exalenz Bioscience, the latter of which was acquired by Meridian Bioscience. Mr. Rubinstein also held the position of CEO at Taro Pharmaceuticals (Nasdaq: TARO), which was subsequently acquired by Sun Pharmaceuticals. Mr. Rubinstein's appointment follows the tenure of Mr. Assaf Segal, who has stepped down from the Board.

Mr. Segal's resignation was not the result of any disagreement with the Company, its management, or the Board.